PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsONVANSERTIB
ONVANSERTIB
Onvansertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against serine/threonine-protein kinase PLK1. In addition, it is known to target serine/threonine-protein kinase PLK2, serine/threonine-protein kinase PLK3, and receptor-type tyrosine-protein kinase FLT3.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
14 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD015179——13——14
Pancreatic ductal carcinomaD021441——12———3
Pancreatic neoplasmsD010190EFO_0003860C2522———3
AdenocarcinomaD000230——12———3
LeukemiaD007938—C9521———2
Myeloid leukemia acuteD015470—C92.011———1
Myeloid leukemiaD007951—C9211———1
Prostatic neoplasmsD011471—C61—1———1
Castration-resistant prostatic neoplasmsD064129———1———1
Lung neoplasmsD008175HP_0100526C34.90—1———1
Show 5 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369—C801————1
Myelomonocytic leukemia chronicD015477—C93.11————1
Myelomonocytic leukemia acuteD015479—C92.51————1
Myelomonocytic leukemia juvenileD054429—C93.31————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameONVANSERTIB
INNonvansertib
Description
Onvansertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against serine/threonine-protein kinase PLK1. In addition, it is known to target serine/threonine-protein kinase PLK2, serine/threonine-protein kinase PLK3, and receptor-type tyrosine-protein kinase FLT3.
Classification
Small molecule
Drug classserine/threonine kinase inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CN1CCN(c2ccc(OC(F)(F)F)c(Nc3ncc4c(n3)-c3c(c(C(N)=O)nn3CCO)CC4)c2)CC1
Identifiers
PDB—
CAS-ID1034616-18-6
RxCUI—
ChEMBL IDCHEMBL1738758
ChEBI ID—
PubChem CID—
DrugBank—
UNII ID67RM91WDHQ (ChemIDplus, GSRS)
Target
Agency Approved
PLK1
PLK1
Organism
Homo sapiens
Gene name
PLK1
Gene synonyms
PLK
NCBI Gene ID
Protein name
serine/threonine-protein kinase PLK1
Protein synonyms
cell cycle regulated protein kinase, PLK-1, polo (Drosophia)-like kinase, Polo-like kinase 1, Serine/threonine-protein kinase 13, STPK13
Uniprot ID
Mouse ortholog
Plk1 (18817)
serine/threonine-protein kinase PLK1 (Q07832)
Alternate
PLK2
PLK2
PLK3
PLK3
FLT3
FLT3
Organism
Homo sapiens
Gene name
PLK2
Gene synonyms
SNK
NCBI Gene ID
Protein name
serine/threonine-protein kinase PLK2
Protein synonyms
hPlk2, hSNK, PLK-2, Polo-like kinase 2, Serine/threonine-protein kinase SNK, Serum-inducible kinase
Uniprot ID
Mouse ortholog
Plk2 (20620)
serine/threonine-protein kinase PLK2 (P53351)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 134 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
9 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use